コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 before and after instillation of an emulsion eye drop.
2 ot that can be administered as a traditional eye drop.
3 , blood pressure, heart rate, mydriatic, and eye drops.
4 P was 12.2 +/- 2.2 mmHg while on 1.1 +/- 0.9 eye drops.
5 tervention group) or placebo (control group) eye drops.
6 uld be allowed to pass after instillation of eye drops.
7 efore and after the treatment with 0.05% CsA eye drops.
8 ffective and efficient delivery devices than eye drops.
9 hosts were challenged with OVA (Texas-Red+) eye drops.
10 henicol eye drops and 163 to receive placebo eye drops.
11 jection, intramuscular injection, or topical eye drops.
12 67% of participants preferred spray over eye drops.
13 female and 18 589 [71%] male) prescribed PGA eye drops.
14 5+ without glaucoma who do not regularly use eye drops.
15 showed improvement after the use of HP-Guar eye drops.
16 ized to either latanoprost 0.005% or placebo eye drops.
17 th care system vs conventional postoperative eye drops.
18 given along with topical trifluoridine, 1%, eye drops.
19 control group who received preservative free eye drops.
20 s of IVT injections and positive factors for eye drops.
21 was maintained with placebo iontophoresis or eye drops.
22 bconjunctival injection compared to 3x daily eye drops.
23 nstillation of either high- or low-viscosity eye drops.
24 pressure-lowering response to SLT versus PGA eye drops.
25 vision subjects struggled to self-administer eye drops.
26 le maintaining a similar mydriatic effect as eye drops.
27 ts were allocated randomly to initial SLT or eye drops.
28 0.1 ml) combined with topical nepafenac 0.3% eye drops.
29 n, or 70% of the total cost of postoperative eye drops.
30 ensitive gelling formulations and commercial eye drops.
31 n, or by local administration in the form of eye drops.
32 nstallation of pilocarpine and apraclonidine eye drops.
33 nitial selective laser trabeculoplasty or to eye drops.
34 ted eye, compared to brimonidine twice-daily eye drops.
35 e barriers compared to current treatment via eye drops.
36 treated with dexamethasone (DEX) or control eye drops.
37 IOP for one month as an alternative to daily eye drops.
38 most patients elect to start treatment with eye drops.
39 P was 14.3 +/- 3.4 mmHg while on 1.5 +/- 0.8 eye drops.
40 ated with saline plus topical corticosteroid eye drops (0.5% loteprednol etabonate) 4 times daily for
41 e effect of giving this octamer (8mer) as an eye drop 1 hour before ocular infection with HSV-1 was i
43 nge of therapy regimen: Prednisolone acetate eye drops 1% hourly for the first postoperative week.
46 nts were randomized to CsA CE 0.1% (1 mg/ml) eye drops 4 times daily (high dose), CsA CE twice daily
47 e acetate 1%, or ketorolac tromethamine 0.5% eye drops 4 times per day for 5 days commencing immediat
48 ients 1:1 to cenegermin 20 mug/ml or vehicle eye drops, 6 drops daily for 8 weeks of masked treatment
51 However, the rapid clearance of Sunb-malate eye drops administered through topical instillation limi
53 ejection is highest and when typical steroid eye drop administration requirements are particularly on
54 EALM) as well as a qualitative assessment of eye drop administration technique using 3 different crit
59 protein 4 (SDP-4), also known as amlisimod, eye drops against a vehicle control formulation in patie
60 laucoma medication adherence, interest in an eye drop aid, and self-reported adherence (measured by t
62 patients who received topical nepafenac 0.3% eye drops alone and group (2) that included 30 patients
64 centage was --30.29% (-33.03 to -27.55%) for eye drops and -32.29% (-34.87 to -29.70%) for spray.
67 ridocorneal angle, administration of steroid eye drops and circadian rhythmicity were blocked by TRPV
70 enced in using both Mydriasert and mydriatic eye drops and results from the current clinical study of
73 received the gK 8mer or control peptides as eye drops and were then ocularly infected with HSV-1.
74 assay of CFX in pharmaceutical formulation (eye drops) and biological fluid (urine) by a significant
75 tion, spoke English, self-administered their eye drops, and had poor glaucoma medication adherence (d
77 on-invasive ocular delivery methods, such as eye drops, and systemic delivery, have low bioavailabili
78 d that when Mydriasert substituted mydriatic eye drops, annual total costs decreased by 18% and annua
81 sity of Washington who were experienced with eye drop application and were on a steady regimen of sel
82 , in one PDGFRbeta line, we found that focal eye drop application of tamoxifen led to an exclusive Cr
84 Adverse events, most commonly burning after eye drop application, were more common with treatment (3
86 rst-line treatment, both SLT and latanoprost eye drops are effective in newly diagnosed POAG and OHT
87 iple-blinded, randomized trial, two vials of eye drops are given to each participant, one with code A
94 s dermatological ointment, 0.1% cyclosporine eye drops, artificial tears, and 0.5% loteprednol for ke
96 tcomes greatly support the use of pregabalin eye drops as once daily IOP-lowering therapy for glaucom
99 acy and safety of low-concentration atropine eye drops at 0.05%, 0.025%, and 0.01% compared with plac
101 underwent pupil dilation with 1% tropicamide eye drops at the baseline visit, before any laser or med
102 the use of Olopatadine 0.1% or cyclosporine eye drops before DALK (OR = 14.51, 95% CI = 1.43-147.23)
103 The SEE program significantly decreased eye drop bottle contamination, increased eye drop instil
106 by this higher level (>/= 5 times yearly) of eye drop bottle exhaustion were more likely to have poor
108 eported any problem with early exhaustion of eye drop bottles, and this was associated with visual ac
109 s on daily basis was comparable with that by eye drops but with only 20% of drug dose, which suggeste
110 the posterior segment, the convenience of an eye drop combined with intermittent dosing frequency cou
111 ration of G1 or G2 peptide as a prophylactic eye drop completely blocked HSV-1 spread in the mouse co
113 actively immunized mice challenged with OVA eye drops containing 1% anti-CCR7 antibody or isotype co
116 altered eyes were subsequently treated with eye drops containing: a retroviral vector bearing a dnG1
117 an characteristics associated with increased eye drop cost included female gender, greater number of
118 s, patient factors associated with increased eye drop cost included older age, female gender, and rac
120 olerated noncorticosteroid anti-inflammatory eye drop could improve patient outcomes and quality of l
121 dults aged >= 65 years with glaucoma who use eye drops daily and adults aged 65+ without glaucoma who
127 roid and nonsteroidal anti-inflammatory drug eye drops do not hinder the intraocular pressure (IOP)-l
129 hronic ocular diseases, patient adherence to eye drop dosing regimens and the need for frequent intra
130 Glaucoma is commonly treated with daily eye-drop drugs, but adherence to treatment is often unsa
132 rst treatment being more cost-effective than eye drops first at a willingness to pay of pound 20 000
134 htly placebo for 2 years then 0.05% atropine eye drops for 1 year and group 2, nightly 0.01% atropine
136 r 1 year and group 2, nightly 0.01% atropine eye drops for 2 years then rerandomization to placebo ni
139 Clinical trial results of topical atropine eye drops for childhood myopia control have shown incons
140 henylephrine was non-inferior to traditional eye drops for maximum pupil diameter and pupillary const
141 a safe and convenient alternative to topical eye drops for patients undergoing MIVS, but additional a
142 studies of the use of autologous serum-based eye drops for severe dry eye disease and 4 studies of pe
143 trabeculoplasty (SLT) to 0.005% latanoprost eye drops for the treatment of 24-h intraocular pressure
152 iameter was 2.15 mm (1.96 to 2.35 mm) in the eye drop group and 2.48 mm (2.09 to 2.87 mm) in the spra
153 r was 7.65 mm (95%CI 7.45 to 7.85 mm) in the eye drop group and 7.72 mm (7.54 to 7.90 mm) in the spra
154 pressure at more visits (93.0%) than in the eye drops group (91.3%), with glaucoma surgery to lower
155 uloplasty group versus 0.90 (SD 0.16) in the eye drops group, with no significant difference (differe
157 al drug delivery methods, such as antibiotic eye drops, have limitations for intraocular drug deliver
158 ded wear contact lenses was then compared to eye drops in beagle dogs that suffer from spontaneous gl
159 e either 180 mug/mL rhNGF or vehicle control eye drops in both eyes, 3 times daily for 8 weeks, with
160 ve either 180 ug/mL rhNGF or vehicle control eye drops in both eyes, 3 times daily for 8 weeks, with
163 herapeutic efficacy to topically applied Dex eye drops in experimental mouse dry eye model, and these
164 needed ranibizumab administered with placebo eye drops in maintaining BCVA (estimated BCVA gains of 0
166 insert was compared with twice-daily timolol eye drops in patients with open-angle glaucoma (OAG) or
167 he efficacy of N-acetylcysteine amide (NACA) eye drops in reversing the cataract formation induced by
168 -102 (brimapitide) compared to dexamethasone eye drops in the treatment of postoperative ocular infla
169 ular surgery is noninferior to dexamethasone eye drops in the treatment of postoperative ocular infla
170 to the effectiveness of prostaglandin analog eye drops in treating primary open-angle glaucoma, publi
175 sed eye drop bottle contamination, increased eye drop instillation self-efficacy, and demonstrated an
176 lot study, adults with glaucoma demonstrated eye drop instillation success comparable to those withou
178 The main outcome was change in participants' eye drop instillation technique as measured by (1) accur
179 on coaching session, which included teaching eye drop instillation techniques using a motivational in
180 s administered for 52 weeks included placebo eye drops instilled 4 times daily (n=73); pazopanib 5 mg
181 XG-102 900 mug, or placebo) was followed by eye drops instilled 4 times per day for 21 days with pla
184 technique as measured by (1) accuracy of an eye drop landing on the eye, (2) ability to instill an e
185 dex date of PACG diagnosis; 2) no history of eye drops, laser, or cataract surgery unless preceded by
188 ely administration of low-dose dexamethasone eye drops may serve as a simple, cost-effective, and non
190 mmHg at 12 months; the number of hypotensive eye drop medications decreased from 3.07 +/- 1.04 to 1.0
191 Our study demonstrates that corticosteroid eye drops mitigate the acute adverse effects of an exper
192 despite its higher unit cost than mydriatic eye drops, Mydriasert resulted in overall savings in hea
193 Tg-MYOC(Y437H) mice were treated with PBA eye drops (n = 10) or sterile PBS (n = 8) twice daily fo
194 lycol chitosan nanoparticle as a new type of eye drop, namely GCCNP (glycol chitosan cerium oxide nan
195 d with prescribing patterns for prescription eye drops, not subject to the incentives created by Part
196 ymal stromal cells (MSC-exo) administered as eye drops notably alleviate GVHD-associated dry eye dise
197 tivitis on days 3 to 6 compared with placebo eye drops (odds ratio, 0.59; 95% CI, 0.39 to 0.91).
201 ects of systemic and topical administration (eye drops) of GLP-1R agonists in db/db mice; and 3) to e
202 icate that periodic induction, via use of an eye drop, of AAV-mediated secretion of MMP-3 into AH cou
203 anding on the eye, (2) ability to instill an eye drop on the first attempt, and (3) contaminating the
206 ical ointment rather than tacrolimus topical eye drops or ointment showed satisfactory efficacy when
207 l treatment was administered by using 4% CsA eye drops or vehicle (castor oil) four times daily for 1
209 to either Group 1, who received timolol 0.5% eye drops, or Group 2, who received artificial tears for
211 to receive 0.05%, 0.025%, and 0.01% atropine eye drops, or placebo eye drop, respectively, once night
214 nters for Medicare and Medicaid Services for eye drops prescribed for postoperative use after catarac
215 D claims were used to extract information on eye drop prescriptions that were filled during the posto
217 d prevalence of early exhaustion of glaucoma eye drops prior to a scheduled refill, and associated ri
221 icipants, use of short-term topical atropine eye drops ranging from 0.01% to 1.0% for a duration of 2
225 ation, and preferable to difficult and toxic eye-drop regimens.Immunochromatographic assay is an effe
227 nt factors, such as permanent treatment with eye drops, repeated surgeries, and heritability of the d
228 5%, and 0.01% atropine eye drops, or placebo eye drop, respectively, once nightly to both eyes for 1
230 , 0.44 [95% CI, 0.24 to 0.60]; P < .001) and eye drops (rho, 0.47 [95% CI, 0.27 to 0.62]; P < .001).
231 ng low-vision patients about difficulty with eye drop self-administration and recommending eye drop a
236 f corneal angiogenesis showed that aganirsen eye drops significantly inhibited corneal neovasculariza
240 ric preservative-free latanoprost 0.05 mg/ml eye drops solution, in lowering IOP when compared to the
243 lf-efficacy was assessed using the validated Eye Drop Technique Self-Efficacy Scale (EDTSES) survey a
244 pically administered prodrug delivered as an eye drop that is readily converted to the active compoun
245 d with artificial tear and anti-inflammatory eye drops that are generally administered several times
252 uterization and subsequent VEGF TrapR(1)R(2) eye drops three times per day whereas the monotherapy gr
253 acebo (n = 22) was preoperatively applied as eye drops to 1 eye in patients scheduled for cataract su
254 domly assigned (1:1) to receive 0.5% timolol eye drops to administer twice daily or to receive SLT.
255 sulin levels, and the application of insulin eye drops to decapitated rats still resulted in the accu
256 t insert may provide an alternative to daily eye drops to improve adherence, consistency of delivery,
257 riasert compared with conventional mydriatic eye drops to induce pupil dilation prior to cataract sur
264 riasis with Mydriasert compared to mydriatic eye drops (tropicamide [1%] plus phenylephrine [10%]).
267 3%), congestive heart failure (78%), steroid eye drop use (65%), and the non-emergency vaccination of
268 n of the short duration of action of topical eye drops used against ocular inflammation in dry eyes.
271 and efficacy of short-term, high-dose rhNGF eye drops versus placebo in a cohort of glaucoma patient
272 perties of said drugs, which included liquid eye drops, viscous cold syrup solution, ointment cream,
273 en the combination of prednisolone and NSAID eye drops vs NSAID monotherapy or sub-Tenon dexamethason
275 ith either SLT or prostaglandin analog (PGA) eye drops was assessed at different levels of baseline I
276 evere ROP, the introduction of dexamethasone eye drops was associated with a significant reduction in
279 tin eye ointment and propamidine isethionate eye drops) was administered, resulting in significant vi
283 dule AOR 2.52 (95% CI;1.009-6.29), believing eye drops were not effective AOR 6.35 (95% CI;1.17-34.49
286 h glaucoma who were using at least 3 or more eye drops were recruited from the ophthalmology clinic a
287 ery, with or without the use of IOP-lowering eye drops, were 70%, 72%, 60%, and 44%, for achievement
288 Glaucoma control was generally achieved with eye drops, whereas surgery was necessary in 5 patients (
289 expensive than postoperative corticosteroid eye drops, which have historically been standard care.
292 treatment included hourly dexamethasone 0.1% eye drops while awake, atropine 1% three times daily, a
293 f 5 anti-inflammatory prophylactic regimens: eye drops with a combination of prednisolone, 1%, and ke
295 cal corticosteroids: prednisolone acetate 1% eye drops with or without dexamethasone 0.1% eye ointmen
296 compare the effectiveness of chloramphenicol eye drops with placebo in children with infective conjun